pharmaceuticals
To sponsor this category, click here | subscribe to this category

Aveo Pharma delays IPO, at least briefly

Aveo Pharmaceuticals kept the biotech investment community on pins and needles this morning.

BioSante shares surge as cancer vax performs in small study

Shares of BioSante Pharmaceuticals surged this morning in pre-market trading after the developer said that a 19-patient study demonstrated the promise of its GVAX leukemia vaccine to mop up the stubbornly lingering cancer cells of CML patients taking Gleevec. Researchers said that the 19 patients selected for

Tocagen raises $7.8M; ISTA gets PDUFA date;

Who’s the next biotech buyout target?

With Astellas Pharma and OSI Pharmaceuticals haggling over price, BNet Pharma wonders which biotechs could be next on the buyout menu.

Alnara rises from Altus’ ashes

Just 16 months after raising $20 million in its first round of funding, Massachusetts-based Alnara Pharmaceuticals

OSI shares soar as Astellas brawls over rejected bid

Astellas’ hostile bid to acquire OSI Pharmaceuticals –along with its

Astellas makes $3.5B hostile bid for OSI

Astellas Pharma announced today that it has made a $3.5 billion

Anthera delays IPO and sends a chilling message

Biotech companies eager to dust off their old IPO plans may want to wait awhile longer. Anthera Pharmaceuticals, a classic drug developer with high hopes and no steady income, opted to delay its initial public offering yesterday rather than brave the chilly investment scene. The underwriters didn’t say exactly what was holding them back from their plan to sell 4.61 million shares at $13 to $15 a share

Salix braces for harsh panel review of Xifaxan

Salix Pharmaceuticals is headed for its scheduled showdown today with a panel of FDA experts who are expected to grill the company on Xifaxan (rifaximin), a drug that is being prepped for the hepatic encephalopathy market.

Tioga raises $18M for Phase III clinical trial

San Diego-based Tioga Pharmaceuticals has rounded up $18 million to fund a late-stage trial which will enroll 600 patients with